Log in to search using one of your social media accounts:

HIV Mutates Around Promising Gene Editing Technology (CRISPR-CAS 9)
HIV can defeat efforts to cripple it with CRISPR gene-editing technology, researchers say. And the very act of editing — involving snipping at the virus’s genome — may introduce mutations that help it to resist attack. At least half a dozen papers over the past three years have explored using the popular CRISPR–Cas9 gene editing technique to combat HIV, but the latest finding, described in a (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 7, 2016 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Switching HIV+ Patients From Stribld to Genvoya Improved Proteinuria but Not eGFR
CROI 2016 Conference Abstract Number:  795 Safety of Tenofovir Alafenamide in Renal Impairment Author(s):  Anton Pozniak2, Jose R Arribas3, Samir K. Gupta4, Frank A. Post5, Anchalee Avihingsanon6, Gordon Crofoot7, Kenneth A. Lichtenstein8, Moti Ramgopal9, Ploenchan Chetchotisakd10, Marshall W. Fordyce11 Clinical Research, Gilead Sciences Inc, Foster City, CA, United States. 2 (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 7, 2016 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

New HIV Drug Has Potential for Weekly or Once-Yearly Dosing
One of the surprises at CROI 2016 was the first virological data from a new highly potent NRTI that in a slow-release formulation has the potential for annual dosing and that is undergoing research as both treatment and PrEP.In an oral late-breaker, Jay Grobler from Merck presented results from a dose-ranging study in macaques to develop a model for phase 1 studies with MK-8591 (EFdA).1Baseline (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 7, 2016 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Life Expectancy Rising in HIV Group Over 50, But Still Lags General Population
Estimated median survival in the HIV group rose from 11.8 years in 1996-1999 to 17.8 years in 2000-2005 and to 22.5 years in 2006-2014. Median survival in general population controls was 30.2 years across all three periods. Mortality rate ratio comparing HIV-positive people with controls was highest among 50- to 55-year-olds (3.8) and declined in each older age group. But in the oldest age group (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - April 7, 2016 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

HIV-related wasting can have long-term consequences
People who suffered wasting in the past more vulnerable to frailty in later life Michael Carter Published: 30 November 2015 HIV-associated wasting can have a long-term impact on physical function and quality of life, according to research from the United States published in the online edition of AIDS. The research was conducted by (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 29, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

HPV and HIV: What You Need to Know About Anal Cancer (Video)
Men who have anal sex with men (MSM) are more likely to get anal HPVthan men who only have sex with women. Researchers estimate that the prevalence of anal HPV among men who only have sex with women is around 15% while anal HPV prevalence for MSM is around 60%. If you add HIV into the mix, infection risk goes up still—one study published by HIV Medicine found that 77% of MSM with HIV were also (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 27, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Best Posts on Aging with HIV from TheBody.com This Week
Forum on Aging With HIV: H. Pylori and HIV: What Do I Need to Know? (Editor's Pick)               Forum on Aging With HIV: H. Pylori and HIV: What Do I ... I am very familiar with H. Pylori. I was diagnosed with it using a urea breath test 2 years ago when I was diagnosed with lymphoma on the stomach wall. This was cau... View on www.thebody.com Preview by Yahoo   (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 11, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Webcast : Beyond the Berlin Patient- How Researchers Are Now Trying to Cure More HIV+ People
Webcast : Beyond the Berlin Patient- How Researchers Are Now Trying to Cure More HIV+ People By Nelson Vergel We all read headlines almost weekly about the latest HIV cure.   After years of being exposed to these inflamed news reports, we may get desensitized to the fact that there is actually progress being made in that field.  Ever since Timothy Brown was proven to be cured, the (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 9, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Two New HIV Studies Give Access to Research Medications to People with Multi-Drug Resistance
By Nelson Vergel.  SalvageTherapies.org No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their viral (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 9, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Webcast Transcript: All You Need to Know About the Use of Truvada to Prevent HIV Infection (Pre-Exposure Prophylaxis- PrEP)
TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) WITH DAMON JACOBS AND NELSON VERGEL Scott:           Hello everybody. Scott Sillary here with Viral Marketing. I'm here with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It's going to be fantastic. Nelson, tell us a little bit about what we're going to be going through today. Nelson:           (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 27, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT)
Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person and clinicians. Please RSVP by clicking "Yes" (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 22, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Frapsauce C, et al. Hum Reprod. 2015. Authors Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1.Author information 1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-Hôpitaux de (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 23, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed's (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 15, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus
Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015 Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA Moussa Laanani1,2, 1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University, Le Kremlin-Bicêtre, France 2APHP, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 3, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Most Important HIV Research Reports from CROI 2015
From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies - the new attachment inhibitor & the new maturation inhibitors, as well as the safety & efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement for TDF in their ART regimen which will likely (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 2, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week
January 29, 2015 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - January 29, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population.
Authors Allavena C1, Guimard T2, Billaud E3, de la Tullaye S4, Reliquet V1, Pineau S3, Hüe H3, Supiot C1,Chennebault JM5, Michau C6, Hitoto H7, Vatan R8, Raffi F1. Author information Journal J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19576. doi: 10.7448/IAS.17.4.19576. eCollection 2014. Affiliation (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Groundbreaking HIV vaccine's effects were real – and could be made to work better
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may be possible to push the immune system into (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Cost Effectiveness of Current HIV Cure Approaches
We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART). Methods We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - November 14, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients
Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US. The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent. The granting of orphan status could shorten the time it takes for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 21, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Demystifying HIV Pre-Exposure Prophylaxis
Pre-Exposure Prophylaxis or PrEP is an HIV prevention strategy where an HIV negative person takes a daily pill to reduce their risk of contracting HIV. It's important to note that PrEP is not the same as PEP or Post-Exposure Prophylaxis, which HIV treatment given to individuals within 72 hours after exposure to HIV to prevent infection from taking hold. The only currently approved (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 18, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Video: Three PrEP Myths Busted (One Pill Per Day to Prevent HIV)
(Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 16, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
For Immediate Release October 10, 2014 Release The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 9, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

What You Should Know About Ebola
Important facts summarized in this great figure. (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 7, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

As PrEP Becomes More Available, Couples With One HIV + Partner Consider Treatment
It has been recommended that gay and bisexual men consider taking pre-exposure prophylaxis, or PrEP, for HIV prevention, but there is one demographic that, according to many health care professionals, is an ideal candidate for this treatment: HIV-negative men with HIV-positive male partners, relationships that are referred to as serodiscordant. For many of these couples, PrEP may offer a (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 7, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs

Great video that explains how a DEXA scan works for measuring bone, body fat and muscle
This video about how a full body dual-energy x-ray absorptiometry (DEXA) scan works as the best way to measure body composition.  However, few clinics provide it since they only use DEXA to measure bone density in the lower back and pelvis. It required special calibration for a full body scan. Talk to your doctor is he can find a local clinic that can do a full body DEXA scan. Your insurance may (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 11, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Fwd: Hot Topics: Our Inner Demons; How Bad Is Smoking?; Once-Monthly Treatment?; and More
If you have trouble reading this email, you can see the online version at: www.thebody.com/topics.html July 9, 2014 Visit the Forums Read Past Email Newsletters Change/Update Subscription  Living With Our Doubts, and Our Inner Demons To the (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 9, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

5 Min Video: How Does the Immune System Work?
Great video made by drawing and explaining the role of each immune cell. (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 7, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Fwd: Hot Topics: Disclosing After Sex; Is My Decline Inevitable?; Is "Empty Stomach" a Must?; and More
If you have trouble reading this email, you can see the online version at: www.thebody.com/topics.html June 17, 2014 Visit the Forums Read Past Email Newsletters Change/Update Subscription  We Already Had Sex; How Do I Disclose? I've been on a few dates with this (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 17, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Video: all you need to know about testosterone
Nelson Vergel speaks about how to know if you need testosterone replacement, how to diagnose low testosterone, all testosterone treatment options, how to maximize benefits (increase muscle mass, mood, energy, sex drive and erectile quality) and minimize side effects (acne, increased red blood cells, etc).  For more information and to ask questions visit: ExcelMale.com (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 12, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

What to do if you just got diagnosed HIV positive?- Video
Nelson Vergel explains each one of the steps that need to be taken after a HIV diagnosis. (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 12, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Treatment News : Treating Leaking Gut May Slow Progression of HIV Disease
A kidney drug was able to decrease gut related immune activation in monkeys http://www.poz.com/articles/leaking_gut_761_25741.shtml (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 11, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Hot Topics: Slowing CD4 Decline; Pill Care on Road Trips; Assessing Your Brain Health; and More
If you have trouble reading this email, you can see the online version at: www.thebody.com/topics.html June 10, 2014 Visit the Forums Read Past Email Newsletters Change/Update Subscription  Can I Slow My CD4 Decline Without Taking Meds? I'm a woman who's been living with HIV for four years, but hasn't started medications. I'm in good health, but my CD4 count is (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 10, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

In HIV News: Vitamin D Deficiency Impact; Hepatitis C Research Recap; Lower Prostate Cancer Risk; and More
  If you have trouble reading this e-mail, you can read the online version at: www.thebodypro.com/newsletter.html  Top Stories on TheBodyPRO.com: June 10, 2014 FEATURED STORIES Vitamin D Deficiency When Starting Treatment Linked With Increased HIV (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 10, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Injection Every 3 Months to Prevent HIV- Study in San Francisco Enrolling Now
There's a new clinical trial about to get started in SF looking for 25 men or transwomen who are at relatively low risk for HIV to test the safety, tolerability and acceptability of a very long acting (injected once every three months) for Pre-exposure prophylaxis (PrEP). If that sounds like you or someone you know, you can get more info by calling 415-881-7190 (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 9, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

HIV-Positive Venezuelans Are Desperately Seeking HIV Medications- Please Help
Even though Venezuela is the third largest oil exporter to the United States and has the largest oil reserves in the world, you would not know that if you visited the country now. The country's infrastructure is in ruins. State officials have been able to pocket much of the oil revenues and imposed illogical dollar exchange restrictions that are suffocating the economy and its people. The (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 6, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Statin Therapy Does Not Improve Cardiovascular Risk for Patients With HIV and Low HDL
The main lipid abnormality of people living with HIV is low high density lipoprotein (HDL).  There are 5 subfractions of HDL: 2a, 2b, 3a, 3b, and 3c, from largest (and most effective in cholesterol removal) to smallest (and least effective). Neither pravastatin nor rosuvastatin changes the distribution of high-density lipoprotein (HDL) subfractions in patients who are HIV-seropositive with (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 5, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Bill sponsored by HIV-Positive Legislator Advances Tuesday to Help People with HIV-related Lipodystrophy
The bill was sponsored by Carl Sciortino, one of the nation’s few openly gay and openly HIV-positive legislators. The 35-year-old has since stepped down from the legislature to serve as executive director of the well-respected AIDS Action Committee. The story of the young, handsome Sciortino is remarkable in and of itself. The child of a self-proclaimed Tea Party conservative, he told (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 5, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Aids survivors summit san francisco convened on june 5, 2014 national hiv/aids long-term survivors awareness day
San Francisco, CA — June 5, 2014 is the first-ever National HIV/AIDS Long-Term Survivors Awareness Day (NHALTSAD). On that day, Let’s Kick ASS—AIDS Survivor Syndrome convenes the AIDS Survivors Summit/San Francisco 2014at theSan Francisco LGBT Center on June 5, 2014 from 1:00-9:00 PM. Let’s Kick ASS is bringing together survivors, both HIV-positive and negative, with key Bay Area AIDS (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 5, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

New CDC Guidelines: People at Risk for HIV Should Consider Truvada PrEP
Healthcare providers should advise people at "substantial risk" for HIV infection about pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine, or Truvada, according to new guidelines issued by the U.S. Centers for Disease Control and Prevention (CDC). This includes HIV negative people in an ongoing sexual relationship with HIV positive partners, gay or bisexual men who have had (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - May 28, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.
Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy. Authors Serra MS, et al.  Journal Int J STD AIDS. 2014 May 22. pii: 0956462414536878. [Epub ahead of print] Affiliation Abstract BACKGROUND: Progression of lipodystrophy syndrome is a big challenge in HIV treatment. Nowadays, fat loss at the lower part of buttocks has become (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - May 24, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

The untold side of the movie "Dallas Buyers Club"
The movie Dallas Buyers Club brings attention to a little-recognized part of the AIDS activist movement: the desperate struggle to provide anything that might treat the disease when no treatment was available. AL-721, Compound Q, Peptide T—buyers clubs formed around the country to bring in potential treatments, whether pharmaceutical or botanical, for both the virus and its (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - January 21, 2014 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Activists Condemn Gilead for Exhorbitant Price of Their New Hepatitis C Drug
For Immediate Release December 9, 2013 Contact: Lynda Dee 410-332-1170 or lyndamdee@aol.com Fair Pricing Coalition Condemns Gilead Sciences on the High Price of New Hepatitis C Drug Sovaldi™, and Urges Rapid and Wide Dissemination of Support Program Details for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - December 9, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Briefing at Congress: The Changing Face of HIV/AIDS in America
Briefing:   The Changing Face of HIV/ AIDS in America September 18, 2013  Briefing: 9:30-10:30 a.m. Reception: 10:30-11 :30 a.m. US Congress Capitol Visitors Center, Room SVC 212 Hosted by: AIDS Community Research Initiative of America (ACRIA)  Services and Advocacy for GLBT Elders (SAGE)  National Hispanic Council on Aging Human Rights Campaign Gay Men's Health Crisis (GMHC) (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 9, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Once a Month HIV Medications- Cost Effectiveness
Long-acting antiretroviral (ARV) formulations, now in clinical development, could prolong survival in people with HIV, according to results of a modeling study [1]. But the benefit may hold true only in people with barriers to good adherence. Although long-acting antiretrovirals may not be cheap, the researchers determined they could be "a good value" when used mainly for poorly adherent (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 5, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

Once a Month HIV Medications - Cost Effectiveness
Long-acting antiretroviral (ARV) formulations, now in clinical development, could prolong survival in people with HIV, according to results of a modeling study [1]. But the benefit may hold true only in people with barriers to good adherence. Although long-acting antiretrovirals may not be cheap, the researchers determined they could be "a good value" when used mainly for poorly adherent (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 5, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

HPV vaccine wears off quickly in HIV-positive women
Women with HIV probably need a booster shot of HPV vaccine within 2 years to maintain efficacy, according to a Canadian study of quadrivalent HPV vaccine (Gardasil) in 136 HIV-positive women. Antibody response to the vaccine is strong enough at 2 years to protect about 90% of HIV-negative women against HPV [human papillomavirus]. "But in our population, with approximately a year and a half of (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 2, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

How HIV Providers Should Prepare for Obamacare
The Affordable Care Act: The name alone is enough to make the eyes of clinicians and patients alike glaze over. Yet the impact of the ACA (colloquially called Obamacare) has the potential to be massive when it comes to access to clinical care for HIV-infected people in the U.S. And with more ACA-related changes on the near horizon, the importance of staying informed has never been greater, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 28, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

What Can We Look Forward to in HIV Cure Research? Conversation With Research Advocate Richard Jefferys
This past March, the 20th Conference on Retroviruses and Opportunistic Infections (CROI) brought an unprecedented flurry of mainstream interest in potential HIV cure strategies. TheBodyPRO.com's Nelson Vergel sat down with leading HIV cure research activist Richard Jefferys for an update on current important aspects, and controversies, in HIV cure research. Jefferys, who coordinates the (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 28, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe
On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions.  One of the concerns was how the price, which didn’t accompany the original company press statement, would be critical for whether dolutegravir finds a significant market. While (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 21, 2013 Category: HIV AIDS Authors: Nelson Vergel Source Type: blogs